Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for ...

Merck ( MRK 0.53%) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

新泽西州拉威 - 全球医疗保健公司Merck & Co., Inc. (NYSE:MRK)今日宣布,其GARDASIL®9 HPV疫苗的三期临床试验在16至26岁日本男性中达到主要和次要终点。与安慰剂相比,该疫苗在减少九种HPV类型引起的持续性肛门生殖器感染方面显示出疗效。 这项名为V503-064的试验共招募了1,059名参与者,旨在减少HPV 6、11、16、18、31、33、45、52和58 ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...